CD8A and cancer: al. [53] identified CD8+ T cells recognizing specific tumor neo-epitopes in nearly 90% of patients with immunotherapy-naïve, heavily pre-treated recurrent advanced EOCs: CD8+ lymphocytes were detected both within tumor tissue (i.e., TILs) and in peripheral blood, with discordant neoantigen specificity and avidity among these two immune cell populations; of note, gene signatures of cancers in which hosts displayed neoantigen-specific peripheral blood T lymphocytes were enriched for genes involved in antigen-processing/presentation pathways and PD-1 signaling.